Indivior Sets October 15 Vote on Supernus Merger; Pro Forma Shows $8B Combined Company
INDV sits 56% above its 52-week low of $22.22.
Summary
Indivior's amended S-4 sets October 15, 2026 for the shareholder vote on its merger with Supernus and includes pro forma financials showing an $8 billion combined company.
Key Events · M&A and Partnerships · INDV
-
Special Meeting Set for October 15
Indivior and Supernus stockholders will vote on the merger on October 15, 2026, with a record date of September 4, 2026. Indivior stockholders vote on the share issuance; Supernus stockholders vote on adopting the merger agreement.
-
HSR Waiting Period Expires September 21
Both companies filed HSR notifications on August 20, 2026. The 30-day waiting period expires September 21, 2026, unless extended or terminated early.
-
Pro Forma Combined Financials Disclosed
The pro forma balance sheet shows $8.0 billion in total assets and $3.6 billion in total liabilities. The $1 billion special dividend to Indivior stockholders is funded by a new $650 million term loan facility.
-
Ownership Split Confirmed
Indivior stockholders will own approximately 56.5% and Supernus stockholders approximately 43.5% of the combined company on a fully diluted basis, based on the 1.5401 exchange ratio.
Analysis · INDV · Life Sciences
This S-4/A amendment finalizes the shareholder vote date (October 15, 2026) and record date (September 4, 2026) for the merger of equals with Supernus, and includes the first detailed pro forma combined financials. The pro forma balance sheet shows a combined company with $8.0 billion in total assets and $3.6 billion in total liabilities, reflecting the $1 billion special dividend to Indivior stockholders funded by a new $650 million term loan. The HSR waiting period expires September 21, 2026, clearing a key regulatory hurdle. While the merger terms were announced August 3, this amendment provides the concrete timeline and financial picture investors need to evaluate the transaction.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 30% of the 1972 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDV was trading at $34.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $22.22 to $42.81. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.